The German Collaborative Glomerulonephritis Therapy Study, which celebrated its 10th anniversary in 1996, has collected data on more than 1,000 patients with biopsy-proven glomerulonephritis. 929 patients could be evaluated and 500 were treated according to at least one of various protocols developed for a randomized controlled trial. Current results show that prednisolone is effective in minimal-change nephropathy, and in combination with other immunosuppressants it can reduce proteinuria in individual cases of focal and segmental glomerulosclerosis, membranous glomerulonephritis and nephrotic IgA nephropathy. The majority of tested treatment protocols did not prove to be superior to symptomatic therapy for long-term outcome.

Adolescent↗

PubMed1993

Modulation of blood pressure and the renin-angiotensin system in transgenic and spontaneously hypertensive rats afer ovariectomy.

Explore the source record for details and available documents.

Animals↗

PubMed1992

EEG-brain mapping. A method to optimize therapy in schizophrenics using absolute power and center frequency values.

In this study EEG-spectral parameters like mean alpha-power values and center frequency values are computed as maps and compared using significant probability mapping. The parameters are used to describe changes of the functional state of the brain after neuroleptic depot injection (Haldol-Decanoate) in schizophrenic patients. The absolute alpha-power increased significantly (p < 0.01), especially within the first week after injection mostly in the left hemispheric regions. The center frequency decreased most significantly (p < 0.02) between the first and second week after haldol depot injection at the right occipital regions. Both parameters are efficient to describe functional changes correlated with clinical symptomatology, even 3-5 days earlier. Thus, EEG power and center frequency mapping can be used very efficiently to estimate the optimal time between sequential neuroleptic depot injections.

Adult↗

PubMed1988

[The share of nursing activities in the work of the nursing personnel in dialysis departments].

Explore the source record for details and available documents.

Hemodialysis Units, Hospital↗

PubMed1983

[Incidence of posthepatic sequelae of acute viral hepatitis C].

There are not yet any ascertained results concerning the prognosis of the non-A/non-B hepatitis not depending on transfusion. In an identical source of infection meanwhile several working teams in the GDR by means of long-term observations for three years control groups of women able to propagate who were incubated by a hepatitis C-virus (of the non-A/non-B group of the hepatotropic viruses), so that first evidence on posthepatitic sequelae after hepatitis C is possible. Of 115 women who were treated with anti-D-globulin contaminated with C virus 57 women fell ill (= 49.5%). Of them 39 patients (3 68.4%) were cured after 3 years, 7 patients (6 12.3%) showed the signs of a residual hepatitis, 10 patients (3 17.5%) showed a chronically persisting and 1 patient (= 1.75%) a chronically active hepatitis. The results presented are compared to those of other working teams of our country.

Acute Disease↗

PubMedDate not supplied

Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.

The aim of the present study was to ascertain the comparative efficacy of cyclandelate, a migraine prophylactic with calcium overload blocking properties, versus propranolol, a non-selective beta-adrenergic blocker, and placebo. Based on different statistical analysis procedures (including time series analysis) a responder and nonresponder evaluation for cyclandelate and propranolol was performed. In addition, an attempt was made to identify the dose relationship of the various drugs on headache parameters. In a double-blind placebo-controlled study 84 patients were treated in a placebo run-in phase (4 weeks). The patients were then randomized by the statistical criterion of placebo responder and nonresponder to either the cyclandelate or the propranolol group. The total treatment period included a low-dosage phase (8 weeks) and high-dosage phase (8 weeks). All patients kept a headache diary before, during and after treatment. The data were assessed by time series analysis (ARIMA), as well as by analysis of variance and nonparametric statistics. Based on ARIMA statistics, 39.3% of the patients showed a significant improvement of migraine during treatment with cyclandelate compared with 29.4% placed on propranolol. Higher doses of cyclandelate and propranolol were more effective. Using the qualitative response-criterion of a 50% reduction in migraine symptoms, cyclandelate showed a response in 67.9% and propranolol in 41.2% of all cases. It can therefore be concluded that cyclandelate as well as propranolol are two comparable substances in the prophylactic treatment of migraine, with cyclandelate showing fewer side effects.

Adolescent↗